Particulate and cytosolic protein tyrosine phosphatase (PTPase) activity was measured in skeletal muscle from 15 insulin-sensitive subjects and 5 insulin-resistant nondiabetic subjects, as well as 18 subjects with non-insulin-dependent diabetes mellitus (NIDDM). Approximately 90% of total PTPase activity resided in the particulate fraction. In comparison with lean nondiabetic subjects, particulate PTPase activity was reduced 21% (P < 0.05) and 22% (P < 0.005) in obese nondiabetic and NIDDM subjects, respectively. PTPase1B protein levels were likewise decreased by 38% in NIDDM subjects (P < 0.05). During hyperinsulinemic glucose clamps, glucose disposal rates (GDR) increased approximately sixfold in lean control and twofold in NIDDM subjects, while particulate PTPase activity did not change. However, a strong positive correlation (r = 0.64, P < 0.001) existed between particulate PTPase activity and insulin-stimulated GDR. In five obese NIDDM subjects, weight loss of -10% body wt resulted in a significant and corresponding increase in both particulate PTPase activity and insulin-stimulated GDR. These findings indicate that skeletal muscle particulate PTPase activity and PTPasel B protein content reflect in vivo insulin sensitivity and are reduced in insulin resistant states. We conclude that skeletal muscle PTFPase activity is involved in the chronic, but not acute regulation of insulin action, and that the decreased enzyme activity may have a role in the insulin resistance of obesity and NIDDM. (J.
Introduction
Insulin resistance is a major pathophysiological abnormality in NIDDM, resulting in reduced rates of insulin-mediated glucose uptake, primarily in skeletal muscle tissue ( 1) . The cellular basis of insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM)' has recently received considerable attention (2) , and it is now clear that in most cases postinsulin phorylation and tyrosine kinase activity are severely impaired in skeletal muscle and other tissues in NIDDM (5) (6) (7) (8) , suggesting that increased protein tyrosine phosphatase activity may contribute to NIDDM-related insulin resistance. In support of this hypothesis, increased skeletal muscle PTPase activity has been recently reported in insulin resistant, nondiabetic Pima Indians (9) .
The purpose ofthis study was to determine the relationship between PTPase activity and insulin action in insulin-sensitive individuals and subjects with varying degrees of insulin resistance. We measured PTPase activity in needle biopsy specimens of skeletal muscle from 20 lean and obese nondiabetic subjects and from 18 subjects with classical NIDDM under basal (fasting) conditions and during hyperinsulinemic glucose clamps. In addition, in five obese NIDDM subjects, the effects of weight loss on skeletal muscle particulate PTPase activity and insulin stimulated GDR were determined. Since PTPase lB is the most likely of the known PTPases to have a major influence on insulin action ( 10), we also compared skeletal muscle PTPase lB protein content in control and NIDDM subjects.
Methods
Materials. y[32PJATP (6, 000 Ci/mmol) and [3H]3-glucose (17.70 Ci/mmol) were obtained from New England Nuclear (Boston, MA); regular human insulin (Novolin R) was kindly provided by Novo Nordisk Pharmaceuticals, Inc. (Princeton, NJ); wheat germ agglutinin agarose was from Vector Laboratories, Inc. (Burlingame, CA); silicotungstic acid was from J.T. Baker Chemical Co. (Phillipsburg, NJ); Triton X-100 and AG 1-X2 acetate were purchased from Bio-Rad Laboratories, Inc. (Richmond, CA); SEP-PAK C 18 cartridges were from Waters Associates (Milford, MA). The synthetic peptide, Thr-Arg-Asp-IleTyr-Glu-Thr-Asp-Tyr-Tyr-Arg-Lys, which contains the amino acid sequence between residues 1142 and 1153 of the insulin receptor fl-sub- Subjects. 18 subjects with NIDDM and 20 nondiabetic subjects with normal glucose tolerance (12) participated in the studies. The clinical and metabolic characteristics of the subjects are listed in Table  I . The NIDDM subjects were healthy, except for diabetes, and did not have significant diabetic complications. All NIDDM subjects were initially treated with either diet (n = 2) or oral hypoglycemic agents (n = 16). Oral hypoglycemic agents were discontinued > 2 wk before study. No subject was on any other medication known to influence carbohydrate or lipid metabolism. Determination ofglucose disposal rate (GDR). The GDR of each subject was determined by hyperinsulinemic glucose clamp. Procedures ofthe clamp study have been previously described in detail (13) .
Briefly, [3H]3-glucose was constantly infused (0.6 ,Ci/min) during the entire study period, starting 2 2.5 hours before insulin infusion. In 15 NIDDM and all nondiabetic subjects, insulin was infused in a primed continuous manner at 720 pmol * M-2 min -'with plasma glucose held constant at 5 mM for 4-5 h. In three NIDDM subjects, insulin was infused at a rate of 300 pmol M 2' min-', and glucose was maintained at 10-20 mM. The GDR obtained during these hyperinsulinemic hyperglycemic clamps was comparable to that obtained from hyperinsulinemic (720 pmol. M-2 min-') euglycemic (5 mM) clamps (13) . GDR was calculated during the last 60 min ofeach clamp study from the isotopically determined glucose disappearance rate (Rd), except when glucose infusion rates were greater than Rd. Rd or glucose infusion rates were corrected for changes in glucose concentration and urinary glucose loss (during hyperglycemic studies) to reflect the actual rate of GDR.
Muscle biopsy. Percutaneous muscle biopsies were obtained from the vastus lateralis muscle using the procedure previously described in detail (14) . The specimen was blotted to remove blood, frozen in liquid nitrogen within 10 s, and stored in liquid nitrogen until assayed.
Weight loss of obese NIDDM subjects. A hyperinsulinemic (720 pmol. M2-min-') euglycemic (5 mM) clamp and muscle biopsy were performed in five obese NIDDM subjects before and after a period ofdiet-induced weight loss. The characteristics ofthis study population are shown in Table II (9) . Briefly, muscle biopsies were mechanically homogenized in a Potter-Elvejhem homogenizer (Caframo, Wiarton, Ontario, Canada) in 10 vol of buffer A (25 mM imidazole, pH 7.5, 4 mM DTT, 2 mM benzamidine, 0.2 mM PMSF, and 4 gg/ml leupeptin). Homogenates were centrifuged 20 min at 350,000 g and supernatants were retained as the "cytosolic fraction". Pellets were resuspended in the same volume of buffer B (buffer A supplemented with 200 mM NaCI and 0.5% Triton X-100), set on ice for 30 min, and recentrifuged 10 min at 14,000 g. Supernatants collected after treatment with Triton X-100 were retained as the "particulate fraction." All manipulations were carried out at 4°C.
Determination ofprotein tyrosine phosphatase (PTPase) activity.
PTPase activity was measured using a synthetic peptide substrate (IRP) homologous to the major site oftyrosine autophosphorylation of the human insulin receptor. amino acids 1142-1153 (11). The substrate contains three potential sites of tyrosine phosphorylation. It was phosphorylated in vitro by purified activated human insulin receptor in the presence of y[32P]ATP and purified as described (16). The dephosphorylation reaction was carried out at 30°C in a final volume of 50 gl, containing 160 Mg/ml (particulate) or 1.5 mg/ml (cytosolic) protein, with 1-5 M1M 32P-IRP and 20-25 MM nonradioactive P-IRP (an average of 44,000 cpm/reaction), unless otherwise stated, in 25 mM imidazole, pH 7.0, 1 mg/ml BSA, and 0.1% (vol/vol) ,B-mercaptoethanol. After 6 min, the reaction was terminated by adding a threefold excess volume ofice-cold 10% TCA. 32Pi released from the labeled substrate was measured after organic extraction by the method of Shacter (17) . PTPase activity was defined as the percent of original cpm released -min-' . Mg protein-'. The reaction was linear with respect to time and amount ofPTPase activity present, until 2 40% ofthe 32Pi had been released. All determinations were performed within the linear range. In some cases, PTPase activity was also determined using tyrosine-phosphorylated RCM-lysozyme as the substrate (18) . Protein concentrations were determined by the method of Bradford (19) .
Immunoblot analysis of PTPaselB protein.
To quantitate the amount of PTPase l B in skeletal muscle, particulate proteins were immunoblotted using a monoclonal anti-PTPaselB antibody, FG6-1G (20) . The antibody reacts with a conserved epitope in the catalytic domain of PTPasel B (20) . Equal amounts of particulate protein (100 
Results
Skeletal muscle PTPase activity in nondiabetic and NIDDM subjects. Basal particulate and cytosolic PTPase activities were measured in skeletal muscle from nondiabetic and NIDDM subjects, using phosphorylated IRP as the enzymatic substrate. The results are shown in Fig. 1 . Approximately 90% of total PTPase activity was associated with the particulate fraction (0.283±0.014 vs 0.027±0.021% of original cpm released* min-' *,ug protein'-in the particulate and cytosolic fractions from nondiabetic subjects, and 0.220±0.011 vs 0.026±0.017% of original cpm released. min-' *,ug protein-' in the particulate and cytosolic fractions from NIDDM subjects, respectively). Basal particulate PTPase activity was 22% (P < 0.005) lower in NIDDM subjects than in nondiabetic subjects (0.220±0.011 vs 0.283±0.014 percent of original cpm released. minm -' ,g protein-', respectively). In contrast, no difference was detected in cytosolic PTPase activity between NIDDM and nondiabetic individuals.
Results similar to those shown in Fig. 1 were also obtained using phosphorylated RCM-lysozyme as the substrate (Table   0. Basal tyrosine phosphatase activity in fractionated skeletal muscle from nondiabetic and NIDDM subjects. Muscle biopsies were obtained and fractionated as described. Particulate ( 160 .g/ml) and cytosolic (1.5 mg/ml) proteins were incubated with phosphorylated IRP ( 1-5 4M 32P-IRP and 20-25 ,uM nonradioactive P-IRP) at 30°C for 6 min. 32Pi released from 32P-IRP was measured after organic extraction of 32Pi ( 17) . The results represent the mean±SEM for 15 lean control subjects and 18 NIDDM subjects. *P < 0.005 vs nondiabetic by Student's t test. III). Skeletal muscle particulate PTPase activity was 29% lower in NIDDM subjects than in nondiabetic counterparts (P < 0.001 ), while cytosolic PTPase activity was not detectably altered. As a result ofthese observations, all subsequent studies of human muscle PTPase activity were carried out using the particulate fraction only, and the enzyme activity was measured using phosphorylated IRP.
To determine the effects of insulin resistance alone, basal particulate PTPase activity was measured in skeletal muscle from six lean (insulin-sensitive) and five obese (insulin-resistant) nondiabetic subjects. In comparison with insulin sensitive nondiabetic subjects, PTPase activity was reduced 21% (P < 0.05) in insulin resistant nondiabetic subjects.
To confirm the specificity of our assay and to rule out the possible dephosphorylation of either phosphorylated IRP or RCM-lysozyme by nonspecific enzymes contaminating the preparation, we measured PTPase activity in the presence of 100 AtM sodium orthovanadate. The presence of vanadate (an inhibitor ofPTPases) during exposure ofthe substrate to particulate or cytosolic PTPases resulted in the inhibition of phosphate release from the tyrosyl residues of IRP and RCM-lysozyme by > 90% (data not shown).
Effect ofacute insulin infusion on GDR and PTPase activity. To assess the relationship between PTPase activity and insulin action in vivo, we measured GDR and skeletal muscle particulate PTPase activity in nondiabetic and NIDDM subjects before and during hyperinsulinemic clamps. The insulinstimulated values were then compared with corresponding values for basal GDR and PTPase activity. As shown in Fig. 2 , acute insulin infusion for 4-6 h increased glucose disposal rates 5.5-fold in nondiabetic subjects (from 1.84±0.22 to 10.21±0.98 mg.kg-'.min-', P < 0.001) and 2.2-fold in NIDDM subjects (from 2.37±0.32 to 5.32±0.63 mg kg-' min ', P < 0.05 ). In contrast, particulate PTPase activity was unaltered by the acute insulin treatment. Since determination of PTPase activity at a single time point would have failed to detect changes that might have occurred after shorter or longer infusion periods, particulate PTPase activity was additionally measured in skeletal muscle from six nondiabetic subjects before and after hyperinsulinemic clamps of 1, 3, and 6 h duration. No significant alteration in PTPase activity was observed in response to insulin at any of the times tested (data not shown). Therefore, in subsequent studies, only PTPase activity from basal muscle biopsies was used to compare with insulin stimulated GDR.
Although there was no acute change in PTPase activity in response to insulin, a strong positive correlation (0.64, P (Fig. 4) . Weight loss was chosen to assess the potential chronic relationship between these variables because it has been well documented to be an effective means ofimproving whole body insulin sensitivity, glucose tolerance, and peripheral glucose disposal in obese NIDDM subjects (23, 24) . As shown in Fig. 4 , skeletal muscle particulate PTPase activity increased signifi- Relationship between in vivo insulin-stimulated GDR and human muscle particulate PTPase activity measured under basal conditions. PTPase activity was determined as described in Fig. 1 . GDR was determined as described in Methods. Subjects included nine lean and five obese nondiabetic subjects and 14 NIDDM individuals (r = 0.64, P < 0.001 ). Comparison of weight, insulin-stimulated GDR, and PTPase activity before and after weight loss in five obese NIDDM subjects. Particulate PTPase activity was measured as described in Fig. 1 Fig. 5 A shows a representative histogram of PTPase lB protein levels in muscle derived from normal and NIDDM subjects. In all subjects, PTPase1B migrated as a doublet of -50 kD. The cellular content ofboth proteins was decreased in all but one of five diabetic subjects (lane 2). This subject's clinical characteristics also differed from those ofthe others. A hyperinsulinemic clamp was not performed on this individual, but the subject was atypically lean, very physically active, and insulinopenic. Based on our experience, we would expect that he would have considerably less peripheral insulin resistance than the other four diabetics, who were obese, hyperinsulinemic, and minimally active. Similarly, one ofthe control subjects (lane 6) had a relatively low PTPase lB protein content, similar to that found in diabetics. He likewise differed from the other control subjects by demonstrating moderately severe insulin resistance during hyperinsulinemic glucose clamps. As shown in Fig. 5 B, the average amount of PTPase lB was 38% lower in NIDDM subjects than in nondiabetic counterparts (P < 0.05).
Discussion
The purpose of this study was to investigate the in vivo relationship between PTPase activity and insulin action. Phosphorylated IRP was used as the enzyme substrate. PTPase activity was determined in particulate and supernatant fractions of skeletal muscle from insulin-sensitive nondiabetic subjects and insulin-resistant NIDDM subjects. We found 90% of total tissue PTPase activity associated with the particulate fraction of skeletal muscle homogenates from both nondiabetic and NIDDM subjects, in agreement with findings reported in a variety of tissues and cell lines (18, 25, 26) . Particulate PTPase activity was significantly reduced in skeletal muscle of NIDDM subjects in comparison with nondiabetic counterparts. This result differs from the findings of McGuire et al. (9), who observed a 33% increase in basal particulate PTPase activity in nondiabetic insulin-resistant Pima Indians in comparison with insulin-sensitive controls.
Our study differed from the study of McGuire et al. (9) in both the enzyme substrate used and the subject population studied. To determine whether the differences in our findings resulted from the use of different substrates, we additionally measured PTPase activity in skeletal muscle from control and NIDDM subjects using phosphorylated RCM-lysozyme (the substrate used in the earlier study). Our results were similar using either phosphorylated IRP or RCM-lysozyme as the substrate for tissue PTPase activity, negating this possibility. To rule out obvious differences in the two subject populations (NIDDM vs insulin resistant nondiabetic), we examined particulate PTPase activity in skeletal muscle from insulin resistant, nondiabetic subjects. In comparison with insulin sensitive nondiabetic controls, particulate PTPase activity was also reduced in insulin resistant nondiabetic subjects. These observations indicate that reduced PTPase activity is associated with the insulin resistant state. The differences between our findings and those of McGuire et al. (9) remain unclear. It is possible, however, that the mechanisms underlying insulin resistance in Pima Indians are specific to that ethnic group and differ from those in the general population.
At this point, we can only speculate about the reason for decreased particulate PTPase activity in insulin-resistant states such as NIDDM. Since our data indicate no alteration in cytosolic PTPase activity between control and NIDDM subjects, reduced particulate PTPase activity is not caused by redistribution into the cytosolic fraction. However, a number of other factors could be responsible for reduced particulate PTPase activity. Increased proteolytic degradation or decreased synthesis of particulate PTPases could result in the reduced enzyme activity of the insulin resistant state. Alternatively, the activation state of a PTPase inhibitor could be increased in insulin resistance, resulting in the inactivation of particulate PTPases. Finally, insulin resistance could alter the association of some PTPases with regulatory proteins responsible for controlling their activation state, resulting in decreased particulate PTPase activity.
To evaluate the in vivo relationship between PTPase activity and insulin action, particulate PTPase activity was compared with GDR measured under hyperinsulinemic clamp conditions. A strong positive correlation existed between PTPase activity and insulin-stimulated GDR in all subjects, regardless of diabetic status. This finding indicates a positive association between PTPase activity and insulin action in vivo, and suggests that insulin sensitivity, rather than the presence or absence ofNIDDM, determines the level ofparticulate PTPase activity.
Acute insulin treatment did not influence particulate PTPase activity in muscle obtained from either insulin sensitive or NIDDM subjects. The correlation between PTPase activity and insulin-stimulated GDR thus appears to be caused 1160 by chronic changes in PTPase activity. To test this possibility, basal particulate PTPase activity and insulin stimulated GDR were measured in NIDDM subjects before and after a period of substantial weight loss. In NIDDM subjects weight reduction increased both insulin stimulated GDR and skeletal muscle PTPase activity. The increases in both PTPase activity and GDR with weight loss provide further evidence for a positive association between PTPase activity and insulin action, indicating that PTPase activity is regulated by factors involved in the chronic improvement of GDR.
The reason for the positive association between PTPase activity and insulin action is not clear. However, the association could result from the PTPase-dependent activation ofan insulin action cascade. It has been shown that PTPase activity is essential for insulin-stimulated glucose uptake in 3T3-LI adipocytes (27) . It is possible that hormone-induced PTPase activity may mediate insulin action by dephosphorylating phosphotyrosines that negatively regulate the signaling potential of intermediates, such as the Src-type tyrosine kinases (28-30). Thus, the reduced PTPase activity observed in insulin-resistant nondiabetic subjects and NIDDM subjects might be responsible for the impaired insulin action and subsequent insulin resistance in these patients. Alternatively, the positive association between the enzyme activity and insulin action could arise from changes in PTPase activity resulting from differences in insulin action. Experiments that will discriminate between these two possibilities are currently under way in our laboratory.
To test the possibility that the reduced PTPase activity that accompanies NIDDM is caused by decreased expression of PTPase 1 B, we measured PTPase 1 B protein levels in skeletal muscle from nondiabetic and NIDDM subjects by Western blot analysis, using a monoclonal antibody against human placental PTPase l B. Two distinct protein bands with molecular masses -50 kD were detected in both subgroups. These two different forms of PTPase 1 B could result from posttranslational processing of the protein, or they could be encoded by alternatively spliced RNA species. It is also possible that the monoclonal antibody we used recognized a second PTPase, sharing sequence homology with the catalytic domain of PTPase lB. The cellular content ofboth proteins was decreased in all but one of five diabetic subjects. The reason for higher PTPase lB protein levels in one of the five diabetic subjects may relate to the clinical characteristics of this patient, who differed from the other diabetic subjects as mentioned in Results. In NIDDM patients, the average PTPase l B protein content was 38% lower than in nondiabetic counterparts (P < 0.05). These findings can explain, at least in part, the mechanism of reduced PTPase activity in NIDDM. The mechanism through which PTPase lB protein content itself is impaired is not clear, but could be accounted for through either decreased PTPaselB biosynthesis and/or increased degradation of PTPase lB protein.
In summary, basal particulate PTPase activity is significantly reduced in skeletal muscle from obese, insulin-resistant, non-diabetic subjects and NIDDM subjects in comparison with lean, insulin-sensitive, nondiabetic controls, and is associated with a decreased quantity of PTPase lB protein as well. Skeletal muscle PTPase activity varies in nondiabetic and NIDDM subjects in a manner that correlates strongly with GDR, and is increased after weight loss in a manner parallel to the improvement of GDR. In conclusion, skeletal muscle PTPase activity is positively correlated with insulin action and regulated by factors involved in the chronic stimulation of GDR. Reduced PTPase activity might play an important role in the insulin resistance of nondiabetic and NIDDM subjects.
